It is great news announced in the Australian Prescriber that Dihydropyrimidine dehydrogenase (DPYD) genotyping (5-fluorouracil, capecitabine) is anticipated to be listed as a new item on the Medicare Benefits Schedule from 1 November 2025.
Read more here: https://australianprescriber.tg.org.au/articles/using-pharmacogenomics-to-personalise-drug-therapy-which-drugs-when-and-how.html